ERBB2 and breast cancer: The National Comprehensive Cancer Network (NCCN) 2021 and the American Society for Clinical Oncology (ASCO) 2007 guidelines recommended an ODX test to assess the chemotherapy benefit for HR+/HER2- patients with lymph-node negative (pN0) or 1–3 positive lymph-nodes (pN1) BC [21,22].